Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology
|
April 28, 2022
DOCK4 Regulation of Rho GTPases Mediates Pulmonary Vascular Barrier Function
Pascal Yazbeck, Xavier Cullere, Paul Bennett, et al.
Drug Safety
|
May 9, 2018
A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials
Asit Parikh, Kristin Stephens, Eugene Major, et al.
Inflammatory Bowel Diseases
|
October 9, 2018
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1
Walter Reinisch, Brian Bressler, Rebecca Curtis, et al.
Gut
|
February 20, 2016
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Jean-Frédéric Colombel, Bruce E Sands, Paul Rutgeerts, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 3, 2008
Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin
Brian G Feagan, Gordon R Greenberg, Gary Wild, et al.
Gastroenterology
|
May 27, 2014
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed
Bruce E Sands, Brian G Feagan, Paul Rutgeerts, et al.
Journal of Crohn'S & Colitis
|
March 24, 2017
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease
Maria Rosario, Jonathan L French, Nathanael L Dirks, et al.
Journal of Crohn'S & Colitis
|
February 1, 2018
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease
Maria Rosario, Jonathan L French, Nathanael L Dirks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2014
Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors
Jonathan Goldman, S Gail Eckhardt, Mitesh J Borad, et al.
The New England Journal of Medicine
|
August 23, 2013
Vedolizumab as induction and maintenance therapy for ulcerative colitis
Brian G Feagan, Paul Rutgeerts, Bruce E Sands, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Arteriosclerosis, Thrombosis, and Vascular Biology
|
April 28, 2022
DOCK4 Regulation of Rho GTPases Mediates Pulmonary Vascular Barrier Function
Pascal Yazbeck, Xavier Cullere, Paul Bennett, et al.
Drug Safety
|
May 9, 2018
A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials
Asit Parikh, Kristin Stephens, Eugene Major, et al.
Inflammatory Bowel Diseases
|
October 9, 2018
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1
Walter Reinisch, Brian Bressler, Rebecca Curtis, et al.
Gut
|
February 20, 2016
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Jean-Frédéric Colombel, Bruce E Sands, Paul Rutgeerts, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 3, 2008
Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin
Brian G Feagan, Gordon R Greenberg, Gary Wild, et al.
Gastroenterology
|
May 27, 2014
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed
Bruce E Sands, Brian G Feagan, Paul Rutgeerts, et al.
Journal of Crohn'S & Colitis
|
March 24, 2017
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease
Maria Rosario, Jonathan L French, Nathanael L Dirks, et al.
Journal of Crohn'S & Colitis
|
February 1, 2018
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease
Maria Rosario, Jonathan L French, Nathanael L Dirks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2014
Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors
Jonathan Goldman, S Gail Eckhardt, Mitesh J Borad, et al.
The New England Journal of Medicine
|
August 23, 2013
Vedolizumab as induction and maintenance therapy for ulcerative colitis
Brian G Feagan, Paul Rutgeerts, Bruce E Sands, et al.
Page
of 3